RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...
The product is expected to be available in early 2026. The Food and Drug Administration (FDA) has approved Qivigy (immune globulin intravenous [IV], human-kthm) 10% solution for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback